Robert Lawrence Jr. Email & Phone Number

Washington, DC, US

Baltimore, Maryland, US

Work directly with faculty and researchers within the University of Maryland, Baltimore system (the University of Maryland Medical School, Pharmacy School, etc.) and the officers of the University Technology Transfer Office to identify promising research projects and advance academic innovations by obtaining state and federal grants. Collaborate with TEDCO.

New Canaan, CT, US

Strategic Planning Task Force and Committee Member

• TLC Therapeutics is a specialty pharmaceutical company focused on the commercialization of novel oral liquid reformulations of established medicines. Key milestones and accomplishments include:
• Negotiated a multi-product licensing and manufacturing deal with Rosemont Pharmaceuticals providing TLC with exclusive rights to a portfolio of unique, oral liquid products, including TLC-100 (oral quetiapine.
• Established an equity partnership with Camargo Pharmaceutical Services, the global 505(b)(2) regulatory consultancy
• Developed regulatory/ labeling strategy and led cross-functional Product Development Team (PDT) in execution of development plan for TLC-100 (oral quetiapine suspension 20mg/ml);
• Held multiple engagements with FDA; gained agreement on development program designed to maximize labeling differentiation of TLC-100
• Developed IP strategy for TLC-100; Negotiated Agreement which assigned all intellectual property related to TLC-100 from Perrigo to TLC; Led patent prosecution resulting in grant of multiple US Patents (US # 9,993,486.

Owings Mills, MD, US

• Launched a full-service strategic consulting practice focused on facilitating and optimizing pivotal decisions defining brand strategy, pipeline optimization, lifecycle planning and marketing excellence; Developed a.
• Developed the “Salient Toolkit” a decision-making framework and “best practices” implementation guide (i.e. ”how to develop” target product profiles, product positioning, etc.) designed to facilitate key.
• Built extensive network of subcontractors, and sold and delivered more than 60 engagements generating more than $6.5M in revenue in first five (5) years of operations
• Directly impacted the development and launch of over 30 products, including multiple blockbusters
• Selected by big pharma company as a US and Global “Preferred Supplier” of strategic consulting services
• Partnered extensively with appliedstrategic, ltd. a UK-based consultancy, and merged operations and books of business in 2014

Morrisville, North Carolina, US

Building on successful foundation established at Camargo, I am responsible for expanding the set of strategic consulting solutions offered by Premier Consulting, as well as providing oversight and leading the execution for Premier Consulting's Commercialization Strategy solutions, which enable the organization's “concept to commercialization” offerings..

• Responsible for developing and launching of a new line of commercially focused consulting services and for integrating commercial insights into Camargo's established product development solutions, fully enabling.
• Supported sales / BD efforts and generated >$1.5 million in new business signings and $1.2 million in revenue for commercial engagements within first 15 months.
• Created training materials for new hires and existing scientific team members and provided detailed sales guides and ongoing support for Camargo’s business development and sales team.
• Conducted multiple webinars and published blog posts and other enduring marketing materials designed to increase visibility and awareness of Camargo’s commercial strategy solutions
• Played key role in supporting external due diligence requests and helped to ensure successful sale of Camargo to Premier Research, Inc for ~$130 million in cash.
• Managed multiple workstreams designed to integrate Camargo’s operations into Premier Research’s infrastructure.

Aperta Biosciences is an emerging biopharma company focused on the development of novel treatments for Ocular Surface Disease (OSD), including blepharitis, ocular rosacea, meibomian gland dysfunction, and dry eye disease.

• Tropical Disease Therapeutics, LLC was spun out of Chesapeake Therapeutics, LLC to advance a co-development partnership created to advance a novel form of triclabendazole, a well-known but non-FDA approved treatment.
• Negotiated an exclusive collaboration agreement with Sequent, the sole global API manufacturer of triclabendazole
• Developed regulatory strategy for TDT-01; Gained FDA agreement on abbreviated development plan comprised of small subset of non-clinical studies and a single pivotal Phase III safety and efficacy study
• Oversaw the formulation of TDT-01 and development of manufacturing methods; Initiated stability protocol and initial dose-ranging toxicology studies
• Established and validated clinical operations team located in endemic region of Bolivia; Gained approval for execution of clinical program from SEDES (Bolivian Ministry of Health)
• Conducted an initial epidemiological screening study of over 5,000 school aged children in rural villages of the Bolivian Altiplano to assess the prevalence of fascioliasis

• Created and managed a virtual specialty pharmaceutical company to develop a novel oral liquid formulation of methotrexate (CTx-001) to treat children with acute lymphoblastic leukemia, leading cause of pediatric cancer.
• Negotiated an equity-based services agreement with a CDMO to develop and manufacture CTx-001; Developed pilot formulation for CTx-001
• Applied for and received Orphan Designation from FDA for CTx-001
• Raised $1.2 million in seed capital before competitive development program was identified
• Discontinued CTx-001 program to focus on follow-on opportunities, ultimately resulting in the spinout and funding of Tropical Disease Therapeutics and TLC Therapeutics. Distributed equity in spinout organizations (TLC.

London, GB

• Responsible for maintaining relationships with key clientele and overseeing the execution of global strategic consulting engagements. Accomplishments include:
• Oversaw marketing and commercial strategy practice and expanded service offerings for appliedstrategic, leveraging the “Salient Toolkit”
• Stepped away from day-to-day operations to pursue Chesapeake Therapeutics, LLC

Rahway, New Jersey, US

• Oversaw a diverse group of responsibilities including: primary care promotion and sales, scientific strategy and advocacy, launch planning and management, lifecycle planning, and global commercial leadership for new.
• Led the scientific leadership initiatives including medical education associated with the launch of JANUVIA and JANUMET.
• Led cross-functional teams to develop the portfolio strategy and launch plan associated with major label updates for JANUVIA and JANUMET.
• Led cross-functional team (including creative agency) to develop promotional programs and materials associated label updates. Provided oversight and direction to sales training and ensured 1800 primary care sales reps.
• Franchise marketing point for new pipeline products; Co-led the creation of the global commercial development plan for JANUMET XR (approved in 2012).

Rahway, New Jersey, US

• Key member of extended marketing team responsible for informing strategic and physician promotion business decisions for Januvia®, a first-in-class anti-diabetes treatment. Conducted strategic analyses, designed and.
• Led marketing team in reassessment of physician segmentation strategy and leverage points for Januvia®. Recommendations were incorporated into the US launch strategy.
• Member of marketing sub-team responsible for the development of physician promotional material for Januvia®. Interfaced with creative agency and provided numerous contributions to the development of the branding.
• Oversaw multiple projects in support of the product positioning of Januvia®. Recommendations presented were ultimately accepted by global marketing team.

Rahway, New Jersey, US

Sold Vytorin®, Zetia® and Singulair® to over 300 physician targets in the Philadelphia area. Consistently exceeded market share objectives for area targets by building and leveraging physician relationships and executing tactical plans.

Rahway, New Jersey, US

Constructed, performed and analyzed primary market research on new segment of physician key opinion leaders. Developed comprehensive targeting and messaging strategy designed to activate thought leaders and increase advocacy of Vioxx in local networks.

San Francisco, California, US

Mba, Health Sector Management

Ba, English / History

Education record